pH-dependent inactivation of DT-diaphorase by mitomycin C and porfiromycin

D Siegel, H Beall, M Kasai, H Arai, NW Gibson and D Ross

Molecular Toxicology and Environmental Health Sciences Program, School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262.

Mitomycin C and porfiromycin were found to inactivate rat hepatic DT- diaphorase. Inactivation was pH dependent; little inactivation was detected at pH 5.8, but inactivation increased as the pH was raised to 7.8. Inactivation was concentration and time dependent and displayed pseudo-first-order kinetics. Inactivation was NADH dependent, indicating that reductive metabolism was necessary for inhibition. [3H]Mitomycin C was covalently bound to DT-diaphorase during inhibition, and the stoichiometry for inactivation of DT-diaphorase by mitomycin C was approximately 0.8 nmol of mitomycin C bound/nmol of enzyme. A higher molecular mass product (60 kDa) was detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot analysis of DT-diaphorase preincubated with NADH and mitomycin C at pH 7.8, suggesting that mitomycin C is capable of cross-linking DT- diaphorase. The kinetics of inhibition, requirement for NADH for inhibition, covalent binding of [3H] mitomycin C to DT-diaphorase, and approximate 1:1 stoichiometry suggest that this inactivation process may be mechanism based. Inhibition of DT-diaphorase by mitomycin C and porfiromycin is not limited to a cell-free system and could also be observed in HT-29 cells in culture at pH 7.2. Bioactivation of mitomycin C or porfiromycin by DT-diaphorase is favored at lower pH, whereas at higher pH values enzyme alkylation and inactivation of DT- diaphorase occur. These data suggest that the success of attempts to exploit the elevated DT-diaphorase content of certain human tumors for improved chemotherapeutic response using mitomycin C or porfiromycin will depend on intracellular pH.

Volume 44, Issue 6, pp. 1128-1134, 12/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				R. L. Cowen, A. V. Patterson, B. A. Telfer, R. E. Airley, S. Hobbs, R. M. Phillips, M. Jaffar, I. J. Stratford, and K. J. Williams Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts Mol. Cancer Ther., September 1, 2003; 2(9): 901 - 909. [Abstract] [Full Text] [PDF]

				D. L. Gustafson, D. Siegel, J. C. Rastatter, A. L. Merz, J. C. Parpal, J. K. Kepa, D. Ross, and M. E. Long Kinetics of NAD(P)H:Quinone Oxidoreductase I (NQO1) Inhibition by Mitomycin C in Vitro and in Vivo J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1079 - 1086. [Abstract] [Full Text] [PDF]

				A. J. Warren, D. J. Mustra, and J. W. Hamilton Detection of Mitomycin C-DNA Adducts in Human Breast Cancer Cells Grown in Culture, as Xenografted Tumors in Nude Mice, and in Biopsies of Human Breast Cancer Patient Tumors as Determined by 32P-Postlabeling Clin. Cancer Res., April 1, 2001; 7(4): 1033 - 1042. [Abstract] [Full Text]

				M. He, P. J. Sheldon, and D. H. Sherman Characterization of a quinone reductase activity for the mitomycin C binding protein (MRD): Functional switching from a drug-activating enzyme to a drug-binding protein PNAS, January 23, 2001; (2001) 31314998. [Abstract] [Full Text]

				R. M. Phillips, A. M. Burger, P. M. Loadman, C. M. Jarrett, D. J. Swaine, and H.-H. Fiebig Predicting Tumor Responses to Mitomycin C on the Basis of DT-Diaphorase Activity or Drug Metabolism by Tumor Homogenates: Implications for Enzyme-directed Bioreductive Drug Development Cancer Res., November 1, 2000; 60(22): 6384 - 6390. [Abstract] [Full Text]

				L. P. Schelonka, D. Siegel, M. W. Wilson, A. Meininger, and D. Ross Immunohistochemical Localization of NQO1 in Epithelial Dysplasia and Neoplasia and in Donor Eyes Invest. Ophthalmol. Vis. Sci., June 1, 2000; 41(7): 1617 - 1622. [Abstract] [Full Text]

				M. He, P. J. Sheldon, and D. H. Sherman Characterization of a quinone reductase activity for the mitomycin C binding protein (MRD): Functional switching from a drug-activating enzyme to a drug-binding protein PNAS, January 30, 2001; 98(3): 926 - 931. [Abstract] [Full Text] [PDF]